We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Innovative Nanowafer Enhances Ocular Therapeutic Efficacy

By HospiMedica International staff writers
Posted on 19 Feb 2015
A new study describes a drug-releasing wafer that works better than a medicine dropper for eye injuries, and could help patients recover faster.

Developed by researchers at Baylor College of Medicine (BCM; Houston, TX, USA), the nanowafer is a small, transparent circular disc made of a non-toxic polymer that is similar to a contact lens. The disc contains arrays of nanoreservoirs loaded with axitinib embedded throughout. The slowly dissolving nanowafer retards drug release over time, thus increasing drug residence time on the ocular surface and promoting absorption into ocular tissue. At the end of the stipulated period of drug release, the nanowafer dissolves and fades away.

Image: The axitinib nanowafer (Photo courtesy of Baylor College of Medicine).
Image: The axitinib nanowafer (Photo courtesy of Baylor College of Medicine).

The efficacy of the nanowafer was demonstrated by studying corneal neovascularization (CNV) in a murine ocular burn model. Laser scanning confocal imaging and reverse transcription polymerase chain reaction (RT-PCR) revealed that once a day application of the axitinib nanowafer was twice as effective as that of twice a day delivery of axitinib by topical eye drop therapy. The nanowafer did not affect wound healing and epithelial recovery of the ocular burn induced corneas. The study was published on January 27, 2015, in ACS Nano.

“We found that the nanowafer was much more efficient compared to eye drop treatment. For example, once a day nanowafer treatment has almost twice the efficacy compared to delivering eye drops two times a day,” said senior author Ghanashyam Acharya, MD, an assistant professor of ophthalmology at BCM. “It slowly dissolves and maintains a high concentration of the drug in the tear film and loads up the tissue to provide better efficacy.”

“Eye drops are very inefficient because they are diluted out by the tears and then rapidly washed away from the eye, so there’s very little time for the medication in the drop to be picked up or absorbed by the tissue, and as a consequence the concentration of it doesn’t achieve a high level,” added coauthor Prof. Stephen Pflugfelder, MD.

Related Links:

Baylor College of Medicine



Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Bronchoscope
EB-500

Latest Critical Care News

Stretchable Microneedles to Help In Accurate Tracking of Abnormalities and Identifying Rapid Treatment

Machine Learning Tool Identifies Rare, Undiagnosed Immune Disorders from Patient EHRs

On-Skin Wearable Bioelectronic Device Paves Way for Intelligent Implants